OOIR: Observatory of International Research

Papers

(The TQCC of Endocrine Reviews is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway	542
Endocrine Manifestations and New Developments in Mitochondrial Disease	297
Papillary Craniopharyngioma: An Integrative and Comprehensive Review	261
Correction to: “ER Stress in Cardiometabolic Diseases: From Molecular Mechanisms to Therapeutics”	236
Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention	220
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies	204
Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future	202
LGR4: A New Receptor Member in Endocrine and Metabolic Diseases	195
Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes	185
The Molecular Biology of Midgut Neuroendocrine Neoplasms	178
Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing’s Syndrome	148
A Critical Assessment of Fasting to Promote Metabolic Health and Longevity	144
The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story	130
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies	110
Correction to: “The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty”	110
Stem Cells and Organs-on-chips: New Promising Technologies for Human Infertility Treatment	101
Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors	96
Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?	96
The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism	95
The Biology and Clinical Implications of PCSK7	86
Post-translational Modifications: The Signals at the Intersection of Exercise, Glucose Uptake, and Insulin Sensitivity	82
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status	81
Estrogen Receptor Signaling in the Immune System	78
New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature	72
Erratum to: “The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens”	69

Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas	67
Contemporary Biological Insights and Clinical Management of Craniopharyngioma	62
Time-restricted Eating for the Prevention and Management of Metabolic Diseases	62
Correction to: “Imaging of Pheochromocytomas and Paragangliomas”	61
The Metabolic Role and Therapeutic Potential of the Microbiome	61
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance	59
Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review	58
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia	56
Adiponectin and Adiponectin Receptors in Atherosclerosis	55
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction	55
Subtyping of Primary Aldosteronism by Adrenal Venous Sampling	54
Endotrophin, a Key Marker and Driver for Fibroinflammatory Disease	52
Imaging of Pheochromocytomas and Paragangliomas	52
The Cortisol Awakening Response: Regulation and Functional Significance	50
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood	48